Pharmacotherapy of Personality Disorders

  • Michael R. Liebowitz

Abstract

While the major pathogenic theory of personality disorders held by American psychiatrists is psychoanalytic (Abraham, 1949; Reich, 1949; Knight, 1953; Kernberg, 1975), the biological approach to personality disorders has an equally lengthy history. The modern era began with Kraepelin (1921), who observed affective temperaments in the premorbid history of many manic depressives and their non-ill biological relatives. Later investigators, such as Kretschmer (1936) and Schneider (1959) described constitutional factors thought to underlie both normal and deviant personality types. The major thrust of these studies was the notion that diluted versions of major schizophrenic, affective, and organic disorders could express themselves as chronic, maladaptive patterns of experiencing and functioning in the world; that is, personality disorders. With the modern tools of psychopharmacology, psychobiology, family studies, and clinical studies, these theories can be better tested.

Keywords

Personality Disorder Panic Attack Antisocial Personality Disorder Borderline Personality Disorder Attention Deficit Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abraham K., 1949, Selected Papers on Psychoananlysis ( 1921–1925 ), London, Hogarth Press.Google Scholar
  2. Akiskal H.S., 1981, Subaffective disorders: Dysthymic, cyclothymic and bipolar II disorders in the “borderline” realm. Psychiatr. Clin. North Am. 4: 26–46.Google Scholar
  3. Akiskal H.S., 1979, Khani M.K., Scott-Straus A: Cyclothymic temperamental disorders. Psychiatr. Clin. North Am. 2: 527–554.Google Scholar
  4. Andrulonis P.A., Donnelly J., Glueck B.C. et al: 1980, Preliminary data on ethosuximide and the episodic dyscontrol syndrome. Am. J. Psychiatry 137: 1455–1456.PubMedGoogle Scholar
  5. Aono T., Kaneko M., Numata Y., et al: 1981, Effects of amoxapine, a new antidepressant, on psuedoneurotic schizophrenia. Folia Psychiatr.Neurol. Japan, 35: 115–121.Google Scholar
  6. Bach-Y-Rita G., Lion J.R., Climent C.E., et al: 1971, Episodic dyscontrol: A study of 130 violent patients. Am.J.Psychiatry 127: 1473–1478.PubMedGoogle Scholar
  7. Barnes R.J: 1977, Mesoridazine (Serenitil) in personality disorders–a controlled trial in adolescent patients. Diseases of the Nervous System 38: 258–264.PubMedGoogle Scholar
  8. Baxter L., Edell W., Gerner R., et al: 1984, Dexamethasone suppression test and Axis I diagnosis of in-patients with DSM-III borderline personality disorder. J. Clin. Psychiatry 45: 150–153.PubMedGoogle Scholar
  9. Brinkley J.R., Beitman B.D., Friedel R.O.: 1979, Low-dose neuroleptic regimensin the treatment of borderline patients.Arch Gen Psychiatry 36: 319–326.CrossRefGoogle Scholar
  10. Brown G.L. and Goodwin F.K.: 1986, Human aggression: A biological perspective in Unmasking The Psychopath: Antisocial Personality and Related Syndromes. Edited by Reid W.M., Dorr D., Waller JI. et al. W.W. Norton, N.Y.Google Scholar
  11. Carroll B.J., Greden J.F., Feinberg M., et al: 1981, Neuroendocrine evaluation of depression in borderline patients. Psychiatr. Clin. North Am. 4: 89–98.Google Scholar
  12. Chodoff P.: 1974, Diagnosis of hysteria - an overview. Am. J. Psychiatry 131:1073–1078.Google Scholar
  13. Elliot F.A.: 1977, Propranolol for the control of belligerent behavior following acute brain damage. Ann. Neurol 1: 489–491.CrossRefGoogle Scholar
  14. Faltus F.J.: 1984, The positive effect of alprazolam in the treatment of three patients with borderline personality disorder Am. J. Psychiatry 141: 802–803.PubMedGoogle Scholar
  15. Feighner J.P., Herbstein J., Damlouji N.:1985, Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J.Clin.Psychiatry 46: 206–209PubMedGoogle Scholar
  16. Garbutt J.C., Loosen P.T., Tipermas A., et al: 1983, The TRH test in patients with borderline personality disorder. Psychiatry Res. 9: 107–113.PubMedCrossRefGoogle Scholar
  17. Gardner D.L., Cowdry R.W.: 1985, Alprazolam–induced dyscontrol in borderline personality disorder. Am. J Psychiatry 142: 98–100.PubMedGoogle Scholar
  18. Goldberg S.C., Schulz S.C., Schulz P.M. et al: 1986, Borderline and schizotypal personality disorders treated with low dose thothixene vs. placebo. Arch. Gen. Psychiatry, 43: 680–686.PubMedCrossRefGoogle Scholar
  19. Gunderson J.: 1984, Borderline Personality Disorder. Washington DC, American Psychiatric Press, Inc.Google Scholar
  20. Hedberg D.L., Houck J.H., Glueck B.C.: 1971, Tranylcypromine–trifluoerazine combination in the treatment of schizophrenia. Am. J. Psychiatry 127: 1141–1146.PubMedGoogle Scholar
  21. Hymowitz P., Frances A.J., Hoyt R., et al: 1984, Neuroleptic Treatment of Schizotypal Personalities. Presented at the 137th Annual Meeting of the American Psychiatric Association, Los Angeles.Google Scholar
  22. Kernberg O.F.: 1975, Borderline Conditions and Pathological Narcissim. New York, Jason Aronson Inc.Google Scholar
  23. Kety S.S., Rosenthal D., Wender P.H., et al: 1968, The types and prevalence of mental illness in the biological and adoptive familes of adoptive schizophrenics, in The Transmission of Schizophrenia, ed. Rosenthal D., Kety S.S., Oxford Pergamon Press.Google Scholar
  24. Klein D.F.:1964, Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397–408.PubMedCrossRefGoogle Scholar
  25. Klein D.F.: 1967, Importance of psychiatric diagnosis in the prediction of clinical drug effects. Arch. Gen. Psychiatry 16: 118–126.PubMedCrossRefGoogle Scholar
  26. Klein D.F.: 1975, Psychopharmacology and the borderline patient, in Borderline States in Psychiatry. Edited by Mack JE, New Yor, Grune & StrattonGoogle Scholar
  27. Knight R.P.: 1953, Borderline states. Bull. Menningner Clin. 17: 1–11.Google Scholar
  28. Kraepelin E.: 1921, Manic Depressive Insanity and Paranoia. Edinburgh, E & S Livingston.Google Scholar
  29. Kretschmer E.: 1936, Physique and Character, 2nd edition. London, Routledge.Google Scholar
  30. Leone N.F.: 1982, Response of borderline patients to loxapine and chlorpromazine. J. Clin. Psychiatry 43: 148–150.PubMedGoogle Scholar
  31. Liebowitz J.H., Rudy V., Gershon E.S., et al: 1976, A pharmacogenetic case report: Lithium -responsiveness postpsychotic antisocial behavior. Compr.Psychiatry 17: 655–660.PubMedCrossRefGoogle Scholar
  32. Liebowitz M.R.: 1979, Is borderline a distinct entity? Schizophr. Bull. 5: 23–38.PubMedCrossRefGoogle Scholar
  33. Liebowitz M.R., Klein D.F.: 1979, Hysteroid dysphoria. Psychiatr. Clin. North Am. 2: 555–575.Google Scholar
  34. Liebowitz M.R, Klein D.F.: 1981, Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatr. Clin.North Am. 4: 67–87.Google Scholar
  35. Liebowitz M.R., Quitkin F.M., Stewart J.W., et al: 1984, Phenelzine vs. imipramine in atypical depression:A preliminary report.Arch. Gen. Psychiatry 41: 669–677.CrossRefGoogle Scholar
  36. Liebowitz M.R., Gorman J.M., Fyer A.J., et al: Social phobia: 1985, Review of a neglected anxiety disorder. Arch. Gen. Psychiatry 42: 729–736.CrossRefGoogle Scholar
  37. Liebowitz M.R., Fyer A.J., Gorman J.M., et al: 1986, Phenelzine in social phobia. J. Clinic. Psychopharmacol. 6: 93–98.Google Scholar
  38. Liebowitz M.R., et al: Obsessive compulsive disorder: Paradigmatic shift and an improved prognosis (submitted for publication)Google Scholar
  39. McNamara E., Reynolds C.F., Soloff P.H., et al: 1984, EEG sleep evaluation of depression in borderline patients. Am. J. Psychiatry 141: 182–186.PubMedGoogle Scholar
  40. Millon T.: 1969, Modern Psychopathology: A Biosocial Approach to Maladaptive Learning and Functioning. Philadelphia, WB Saunders.Google Scholar
  41. Nies A., Howard D., Robinson D.S.: 1982, Antianxiety effects of MAO inhibitors, in The Biology of Anxiety, ed. Mathew RJ. New York, Brunner/Mazel.Google Scholar
  42. Quitkin F., Rifkin A., Klein D.F.: 1976, Neurologic soft signs in schizophrenia and character disorders: Organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders. Arch. Gen. Psychiatry 33: 845–853.PubMedCrossRefGoogle Scholar
  43. Ratey J.J., Morrill R., Oxenkrug F:. 1983, Use of propranolol for provoked and unprovoked episodes of rage, Am. J.Psychiatry 140: 1356–1357.PubMedGoogle Scholar
  44. Reich W.:1949, Character Analysis, New York, Noonday Press.Google Scholar
  45. Reyntjens A.M.: 1972, A series of multicentric pilot trials with pimozide in psychiatric practice, I: Pimozide in the treatment of personality disorders. Acta. Psychiatr. Belg. 72: 653–661.PubMedGoogle Scholar
  46. Rifkin A., Quitkin F., Carrillo C., et al: 1972, Lithium carbonate in emotionally unstable character disorder. Arch. Gen.Psychiatry 27: 519–523.PubMedCrossRefGoogle Scholar
  47. Rosenbaum J.F.,Woods S.W., Groves J.E., et al: 1984, Emergence of hostility during alprazolam treatment. Am. J. Psychiatry 141: 792–793.PubMedGoogle Scholar
  48. Rosenthal D., Wender P.H. Kety S.S., et al: 1968, Schizophrenics’ offspring reared in adoptive homes, in The Transmission of Schizophrenia, ed. Rosenthal D, Kety S, Oxford, Pergamon Press.Google Scholar
  49. Schatzberg A.F., Cole J.O.: 1981, Benzodiazepines in the treatment of depressive, borderline personality, and schizophrenic disorders. Br. J. Clin. Pharmacol. 11: 175–225.Google Scholar
  50. Schneider K.: 1959, Clinical Psychopathology. New York, Grune & Stratton. Serban G.: 1984, Borderline and schizotypal personality disorders: Criteria for diagnosis and treatment. Am. J.Psychiatry 141: 1455–1458.Google Scholar
  51. Sheard M.H., Marini J.L., Bridges D.I., et al: 1976, The effect of lithium on impulsive aggressive behavior in man. Am. J. Psychiatry 133: 1409–1413.PubMedGoogle Scholar
  52. Sheehan D.V., Coleman J.H., Greenblatt D.J., et al: 1984, Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. Clin.Psychopharmacol. 4: 66–75.CrossRefGoogle Scholar
  53. Soloff P.H., George A., Nathan R.S,. et al:1986a, Progress in pharmacotherapy of borderline disorders. Arch. Gen. Psychiatry 43: 691–697.PubMedCrossRefGoogle Scholar
  54. Soloff P.H., George A., Nathan R.S,. et al: 1986b, Paradoxical effect of amitriptyline on borderline patients. Am. J. Psychiatry 143: 1603–1605.PubMedGoogle Scholar
  55. Stringer AY, Joseph NC: 1983, Methylphenidate in the treatment of aggression in two patients with antisocial personality disorder. Am. J. Psychiatry 140: 1365–1366.PubMedGoogle Scholar
  56. Stone M.H.: 1979, Contemporary shift of the borderline concept from a subschizophrenic disorder to a subaffectve disorder.Psychiatr. Clin. North Am. 2: 577–594.Google Scholar
  57. Thoren J.P., Asberg M., Cronholm B., et al: 1973, Clomipramine treatment of obsessive -compulsive disorder. Arch. Gen. Psychiatry 37: 311–317.Google Scholar
  58. Tupin J.P. Smith D.B., Clanon T.I., et al: 1973, The long-term use of lithium in aggressive prisoners. Compr. Psychiatry 14: 311–317.PubMedCrossRefGoogle Scholar
  59. Turnquist K., Frances R., Rosenfeld W., et al: 1983, Pemoline in attention deficit disorder and alcoholism: A case study. Am. J. Psychiatry 140: 622–624.PubMedGoogle Scholar
  60. Wender P.H., Reimherr F.W., Wood D.R.: 1981, Attention deficit disorder (minimal brain dysfunction) in adults. Arch. Gen. Psychiatry 38: 449–456.PubMedCrossRefGoogle Scholar
  61. Wood D..R., Reimherr F.W., Wender P.H., et al:1976, Diagnosis and treatment of minimal brain dysfunction in adults. Arch. Gen. Psychiatry 33: 1453–1460.PubMedCrossRefGoogle Scholar
  62. Yerevanian B.I., Akiskal H.S.: 1979, “Neurotic,” characterological, and dysthymic depressions. Psychiatr. Clin. North Am. 2:595–617.Google Scholar
  63. Yudofsky S., Williams D., Gorman J.M.: 1981, Propranolol in treatment of rage and violent behavior in patients with chronic brain syndrome. Am.J. Psychiatry 138: 218–220.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Michael R. Liebowitz
    • 1
  1. 1.Anxiety Disorders ClinicNew York Psychiatric InstituteNew YorkUSA

Personalised recommendations